Furthermore, although a novel small molecular inhibitor of SIRT6, OSS_128167, suppressed in vivo growth of diffuse large B-cell lymphoma cells [19], the study of well-established therapeutic agents targeting SIRT6 have been limited [38], our result suggests that using of an agent targeting the DNA damage repair pathway such as a PARP inhibitor might be helpful for patients in the poor prognostic group of osteosarcoma patients which express high levels of SIRT6. This evidence concerns the gene PARP1 and diffuse large B-cell lymphoma.